once-weekly semaglutide in adults with overweight or obesity Efficacy and safety of once weekly 2·4 mg for weight management a predominantly east Asian population (STEP 7): a double-blind, multicentre, randomised controlled trial Once-Weekly Semaglutide in Adults with

Standiford, L., O'Daniel, M., Hysell, M., & Trigger, C

The active molecule is shared, but manufacturing, regulatory status, and price differ between the two

,

GLP-1 medications can cause nausea, vomiting, and gastrointestinal discomfort particularly when doses are escalated too quickly

This increase supports muscle growth, recovery, and overall wellness

It comes from a research line in biased GPCR signaling that has been building for fifteen years and is finally producing molecules that beat semaglutide on its own metric, in mice, by being smarter about which downstream pathways they activate rather than by being stronger at the receptor itself